pubmed.ncbi.nlm.nih.gov

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway - PubMed

Review

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway

Jiri Polivka Jr et al. Pharmacol Ther. 2014 May.

Abstract

Aberrations in various cellular signaling pathways are instrumental in regulating cellular metabolism, tumor development, growth, proliferation, metastasis and cytoskeletal reorganization. The fundamental cellular signaling cascade involved in these processes, the phosphatidylinositol 3-kinase/protein kinase-B/mammalian target of rapamycin (PI3K/AKT/mTOR), closely related to the mitogen-activated protein kinase (MAPK) pathway, is a crucial and intensively explored intracellular signaling pathway in tumorigenesis. Various activating mutations in oncogenes together with the inactivation of tumor suppressor genes are found in diverse malignancies across almost all members of the pathway. Substantial progress in uncovering PI3K/AKT/mTOR alterations and their roles in tumorigenesis has enabled the development of novel targeted molecules with potential for developing efficacious anticancer treatment. Two approved anticancer drugs, everolimus and temsirolimus, exemplify targeted inhibition of PI3K/AKT/mTOR in the clinic and many others are in preclinical development as well as being tested in early clinical trials for many different types of cancer. This review focuses on targeted PI3K/AKT/mTOR signaling from the perspective of novel molecular targets for cancer therapy found in key pathway members and their corresponding experimental therapeutic agents. Various aberrant prognostic and predictive biomarkers are also discussed and examples are given. Novel approaches to PI3K/AKT/mTOR pathway inhibition together with a better understanding of prognostic and predictive markers have the potential to significantly improve the future care of cancer patients in the current era of personalized cancer medicine.

Keywords: PI3K pathway; Predictive biomarkers; Targeted therapy.

PubMed Disclaimer

Cited by

Novel nanococktail of a dual PI3K/mTOR inhibitor and cabazitaxel for castration-resistant prostate cancer.
Huang Y, Xue X, Li X, Jia B, Pan CX, Li Y, Lin TY. Huang Y, et al. Adv Ther (Weinh). 2020 Oct;3(10):2000075. doi: 10.1002/adtp.202000075. Epub 2020 Jun 30. Adv Ther (Weinh). 2020. PMID: 33072858 Free PMC article.
Applications and prospects of targeted therapy for neuroblastoma.
Wang J, Yao W, Li K. Wang J, et al. World J Pediatr Surg. 2020 Jul 2;3(2):e000164. doi: 10.1136/wjps-2020-000164. eCollection 2020. World J Pediatr Surg. 2020. PMID: 36474924 Free PMC article. Review.
Targeting Signaling Pathway Networks in Several Malignant Tumors: Progresses and Challenges.
He H, Shao X, Li Y, Gihu R, Xie H, Zhou J, Yan H. He H, et al. Front Pharmacol. 2021 May 31;12:675675. doi: 10.3389/fphar.2021.675675. eCollection 2021. Front Pharmacol. 2021. PMID: 34135756 Free PMC article. Review.
Silencing of AP-4 inhibits proliferation, induces cell cycle arrest and promotes apoptosis in human lung cancer cells.
Hu X, Guo W, Chen S, Xu Y, Li P, Wang H, Chu H, Li J, DU Y, Chen X, Zhang G, Zhao G. Hu X, et al. Oncol Lett. 2016 Jun;11(6):3735-3742. doi: 10.3892/ol.2016.4451. Epub 2016 Apr 18. Oncol Lett. 2016. PMID: 27313685 Free PMC article.
Formononetin: A Review of Its Anticancer Potentials and Mechanisms.
Tay KC, Tan LT, Chan CK, Hong SL, Chan KG, Yap WH, Pusparajah P, Lee LH, Goh BH. Tay KC, et al. Front Pharmacol. 2019 Jul 26;10:820. doi: 10.3389/fphar.2019.00820. eCollection 2019. Front Pharmacol. 2019. PMID: 31402861 Free PMC article. Review.

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway - PubMed